跳至主要内容
临床试验/NCT06844240
NCT06844240Enrolling By Invitation不适用

Efficacy and Safety of the XEN63: a Prospective Observational Multicenter Study.

Mario Stirpe19 个研究点 分布在 1 个国家目标入组 96 人开始时间: 2024年11月28日最近更新:
适应症

试验速览

阶段
不适用
状态
Enrolling By Invitation
发起方
入组人数
96
试验地点
19
主要终点
Number of hypotensive eye drops

研究概览

简要总结

The study is prospective, observational, multicenter and has the aim of evaluating the efficacy and safety of the XEN63 implant in patients with primary or secondary glaucoma who require surgery in association or not with cataract surgery, for IOP not controlled by medical therapy, disease progression or intolerance to topical therapy, comparing IOP values before and 24 months after implantation.

详细描述

The study is prospective, observational, multicenter and has the aim of evaluating the efficacy and safety of the XEN63 implant in patients with primary or secondary glaucoma who require surgery in association or not with cataract surgery, for IOP not controlled by medical therapy, disease progression or intolerance to topical therapy, comparing IOP values before and 24 months after implantation. Every patients will be followed for 24 months.

Secondary aims of the study are:

  • Evaluating the hypotensive efficacy of the XEN63 12 months after implantation.
  • Assessing the safety of the XEN63 device after 12 and 24 months after implantation.
  • Comparing the hypotensive efficacy of the XEN63 in glaucomatous patients undergoing the solo procedure and in those undergoing the combo procedure
  • Evaluating the quality of life of patients undergoing XEN63 implantation 12 and 24 months after implantation.
  • Evaluating the association between factors related to the patient, the surgical technique or post-operative management and the hypotensive efficacy of the device during follow-up.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age ≥ 18 years
  • •Diagnosis of primary or secondary open-angle glaucoma according to the diagnostic criteria of 4th edition of the European Glaucoma Society Guidelines.
  • •Need for XEN63 implantation for IOP not controlled by medical therapy, progression of disease or intolerance to topical therapy, in association or not with cataract surgery.
  • •Informed consent freely given and obtained before the start of the study.
  • •The participant has the ability to understand and the willingness to follow the study instructions and is likely to complete all required visits and procedures.

排除标准

  • •Closed-angle glaucoma
  • •Previous trabeculectomy or valve or tube placement.
  • •Presence of conjunctival scarring, previous conjunctival surgery or other conjunctival pathologies (e.g. pterygium) in the target quadrant.
  • •Signs of active inflammation (e.g. blepharitis, conjunctivitis, keratitis, uveitis)
  • •Active iris neovascularization or presence of iris new vessels within 6 months of the date of surgery
  • •Anterior chamber lenses
  • •Presence of intraocular silicone oil
  • •Vitreous in anterior chamber
  • •Altered episcleral venous drainage (e.g. Sturge Webwer syndrome, nanophthalmos)
  • •Known or suspected allergy or sensitization to medications required for the surgical procedure or some component of the device (e.g. glutaraldehyde or porcine derivatives)
  • •History of predisposition to the formation of keloids.
  • •Pregnancy or breastfeeding.

研究组 & 干预措施

Glaucoma

Diagnosis of primary or secondary open-angle glaucoma according to the diagnostic criteria of 4th edition of the European Glaucoma Society Guidelines.

结局指标

主要结局

Number of hypotensive eye drops

时间窗: up to 2 years

Number of hypotensive eye drops

IOP

时间窗: up to 2 years

IOP values before and after 24 months of XEN63 implant.

次要结局

  • Complications(up to 2 years)
  • Post operative management(up to 2 years)
  • IOP(From enrollment to 12 months after surgery)
  • Number of hypotensive eye drops(From enrollment to 12 months after surgery)
  • Quality of life after XEN63 implant(up to 2 years)
  • Surgical tecnique(during the intervention/procedure/surgery)
  • Post operative needling(up to 2 years)
  • Surgical revision(up to 2 years)
  • Glaucoma Symptom Scale(up to 2 years)
  • Surgical technique(during the intervention/procedure/surgery)

研究者

发起方
Mario Stirpe
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Mario Stirpe

Prof

Fondazione G.B. Bietti, IRCCS

研究点 (19)

Loading locations...

相似试验